Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

ConclusionFulvestrant treatment benefited patients with lungw/o liver or nonvisceral metastases. When treating HR ‐positive/HER2‐negative MBC patients with endocrine therapy, it is important to differentiate patients with lung metastases from those with liver metastases.

Source: Cancer Medicine - August 1, 2019 Category: Cancer & Oncology Authors: Min He, Jun ‐Jie Li, Wen‐Jia Zuo, Lei Ji, Yi‐Zhou Jiang, Xi‐Chun Hu, Zhong‐Hua Wang, Zhi‐Ming Shao Tags: ORIGINAL RESEARCH Source Type: research